Paper55652
Immunostimulant therapy with levamisole for rheumatoid arthritis.
Huskisson EC and 5 others. Lancet, 1976. Cited by 187 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Immunostimulant therapy with levamisole for rheumatoid arthritis. Papers, record 55652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/55652
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Immunity, Cellular | Major topic |
| Levamisole | Major topic |
| Animals | |
| Cell Migration Inhibition | |
| Clinical Trials as Topic | |
| Complement System Proteins | |
| Drug Evaluation | |
| Follow-Up Studies | |
| Humans | |
| Hypersensitivity, Delayed | |
| Immunoglobulins | |
| Male | |
| Mice | |
| Pain | |
| Penicillamine | |
| Placebos | |
| Rats | |
| Skin Tests | |
| Time Factors |
Source PubMed
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 187 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39,845,058 | Levamisole, as a viral vaccine adjuvant, induces robust host defense through the modulation of innate and adaptive immune responses. | Front Microbiol | 2024 | https://conductscience.org/library/papers/39845058 | PubMed |
| 39,598,415 | Levamisole Ameliorates Rheumatoid Arthritis by Downregulating the PI3K/Akt Pathway in SD Rats. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39598415 | PubMed |
| 32,762,741 | Standardized ethanol extract of Tinospora crispa upregulates pro-inflammatory mediators release in LPS-primed U937 human macrophages through stimulation of MAPK, NF-κB and PI3K-Akt signaling networks. | BMC Complement Med Ther | 2020 | https://conductscience.org/library/papers/32762741 | PubMed |
| 29,628,691 | Prospective study of immunomodulation in osteoarticular tuberculosis non responsive to anti tubercular therapy. | J Clin Orthop Trauma | 2018 | https://conductscience.org/library/papers/29628691 | PubMed |
| 16,259,711 | Derek Willoughby: an appreciation from a clinical rheumatologist. | Inflammopharmacology | 2005 | https://conductscience.org/library/papers/16259711 | PubMed |
| 16,259,705 | Professor Derek Albert Willoughby (1930-2004). | Inflammopharmacology | 2005 | https://conductscience.org/library/papers/16259705 | PubMed |
| 10,796,440 | Penicillamine for rheumatoid arthritis. | Cochrane Database Syst Rev | 2000 | https://conductscience.org/library/papers/10796440 | PubMed |
| 7,166,176 | Pharmacokinetics of levamisole in healthy subjects and cancer patients. | Eur J Drug Metab Pharmacokinet | 1982 | https://conductscience.org/library/papers/7166176 | PubMed |
| 7,002,065 | Clotrimazole in rheumatoid arthritis. | Ann Rheum Dis | 1980 | https://conductscience.org/library/papers/7002065 | PubMed |
| 6,967,398 | An overview of the current status of levamisole in the treatment of rheumatic diseases. | Drugs | 1980 | https://conductscience.org/library/papers/6967398 | PubMed |
| 6,830,330 | Thymopoietin and levamisole in chronic granulomatous inflammation. | Ann Rheum Dis | 1983 | https://conductscience.org/library/papers/6830330 | PubMed |
| 6,711,389 | Prolonged treatment with D-penicillamine: effects on adjuvant arthritis in the rat. | Agents Actions | 1984 | https://conductscience.org/library/papers/6711389 | PubMed |
| 6,453,230 | Levamisole-induced lichenoid eruptions. | J R Soc Med | 1980 | https://conductscience.org/library/papers/6453230 | PubMed |
| 3,083,661 | Effects of d-penicillamine, levamisole and tiopronin on eicosanoid synthesis by rat gut tissue. | Agents Actions | 1986 | https://conductscience.org/library/papers/3083661 | PubMed |
| 2,668,158 | The stimulation of IL-2 production by anti-rheumatic drugs. | Immunology | 1989 | https://conductscience.org/library/papers/2668158 | PubMed |
| 1,085,681 | The effect of Levamisole on peripheral blood lymphocyte subpopulations in patients with rheumatoid arthritis and ankylosing spondylitis. | Clin Exp Immunol | 1976 | https://conductscience.org/library/papers/1085681 | PubMed |
| 970,290 | Pertussis vaccine oedema: an experimental model for the action of penicillamine-like drugs. | Agents Actions | 1976 | https://conductscience.org/library/papers/970290 | PubMed |
| 930,758 | The effect of drugs in established rabbit monoarticular arthritis. | Agents Actions | 1977 | https://conductscience.org/library/papers/930758 | PubMed |
| 890,415 | Levamisol-induced thrombocytopenia. | Br Med J | 1977 | https://conductscience.org/library/papers/890415 | PubMed |
| 849,643 | Serum effects of mitogenic reactivity in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Technical considerations and lack of correlation with anti-lymphocyte antibodies. | Clin Exp Immunol | 1977 | https://conductscience.org/library/papers/849643 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/55652
GET https://conductscience.org/api/papers/v1/55652/cited_by?page=2